Skip to Content

Trifluoperazine Dosage

Applies to the following strength(s): 10 mg/mL ; 2 mg/mL ; 1 mg ; 2 mg ; 5 mg ; 10 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Geriatric Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Schizophrenia

Initial dose: 2 to 5 mg orally 2 times a day
Maintenance dose: 15 to 20 mg/day
Maximum dose: 40 mg/day

Comment:
-Most patients should reach therapeutic levels in 2 to 3 weeks.

Use: Management of schizophrenia

Usual Adult Dose for Anxiety

Recommended dose: 1 to 2 mg orally 2 times a day
Maximum dose: 6 mg/day
Duration of therapy: Up to 12 weeks

Comment:
-The lowest effective dosage should be used for the shortest duration of time.

Use: Treatment of non-psychotic anxiety

Usual Geriatric Dose for Schizophrenia

Initial dose: 2 mg orally 2 times a day
Maintenance dose: 15 to 20 mg/day
Maximum dose: 40 mg/day

Comment:
-Most patients should reach therapeutic levels in 2 to 3 weeks

Use: Management of schizophrenia

Usual Geriatric Dose for Anxiety

Initial dose: 1 mg orally 2 times a day
Maximum dose: 6 mg/day
Duration of therapy: Up to 12 weeks

Comments:
-Due to the long half-life of this drug, this drug may be given as a once a day dose.
-The lowest effective dosage should be used for the shortest duration of time.

Use: Treatment of non-psychotic anxiety

Usual Pediatric Dose for Schizophrenia

6 to 12 years:
-Initial dose: 1 mg once a day OR 2 times a day
-Maintenance dose: 1 to 15 mg/day

12 years and older:
-Initial dose: 2 to 5 mg orally 2 times a day
-Maintenance dose: 15 to 20 mg/day
-Maximum dose: 40 mg/day

Comments:
-Pediatric patients should be closely monitored or hospitalized.
-Dosing should be determined by symptom severity and the weight of the child. Patients may undergo gradual dose titration until symptoms are controlled or side effects become intolerable.
-Older patients with severe schizophrenia may require doses greater than 15 mg/day to manage their symptoms.
-Most patients should reach therapeutic levels in 2 to 3 weeks.

Use: Management of schizophrenia

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Use is contraindicated in patients with known liver damage.

Dose Adjustments

Small/emaciated patients should begin on the lower end of the dosing range for the management of schizophrenia.

Precautions

US BOXED WARNING:
-INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS: This drug has an increased risk of mortality when administered to elderly patients with dementia-related psychosis. Elderly patients with dementia-related psychosis treated with antipsychotic drugs have an increased risk of death. This drug is not approved for use in patients with dementia-related psychosis.

Safety and efficacy have not been established in patients younger than 6 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Due to the long half-life of this drug, this drug may be given as a once a day dose.
-Use of the liquid formulations should be considered in patients with difficulty taking tablets, who are uncooperative, or pediatric patients.

Storage requirements:
-See manufacturer product information.

Reconstitution/preparation techniques:
-See manufacturer product information.

General:
-All patients on prolonged treatment should be reassessed regularly.
-Use should be avoided as first-line therapy for non-psychotic anxiety.
-This drug has not been effective in the management of behavioral complications in patients with intellectual disabilities.
-Some capsule formulations are equivalent to tablet formulations, but are given once a day. The manufacturer product information should be consulted for more details.
-Treatment is not indicated for symptom improvement and relapse prevention in depressive psychoses.

Monitoring:
-Periodic WBC with differential tests, especially in patients with signs/symptoms of infection/sore throat or with a history of low WBCs or drug-induced neutropenia/leukopenia
-Periodic liver function tests, with increased frequency in patients with signs/symptoms of liver dysfunction
-Blood pressure, especially in patients with impaired cardiovascular systems
-Eye examinations, especially in patients on prolonged treatment
-Heart rate, especially in patients with arrhythmias and/or taking QT prolonging drugs concurrently
-Periodic renal function tests

Patient advice:
-Patients should be warned to avoid abrupt discontinuation of this drug.
-Patients should be instructed to immediately report any signs/symptoms of neutropenia/leukopenia, neuroleptic malignant syndrome, or tardive dyskinesia.
-Inform patients that this drug may cause or impair mental/physical abilities, and they should avoid driving or operating machinery until the full effects of the drug are seen.
-Patients should be advised to speak to a healthcare provider if they are pregnant, intend to become pregnant, or are breastfeeding.

Hide